Lexeo Therapeutics (LXEO) Advances Key Trial Protocol for FDA Approval

Lexeo Therapeutics Inc. (NASDAQ: LXEO) has finalized the trial protocol for SUNRISE-FA 2 and the statistical analysis plan for a Biologics License Application to the U.S. FDA for its gene therapy candidate, LX2006. This submission is aimed at addressing treatment needs in Friedreich's ataxia cardiomyopathy. JPMorgan has reduced its target price from $12 to $9, indicating an upside potential of over 92% despite the cut. The company plans to initiate the pivotal study and enroll its first patient by the end of June, focusing on delivering a potential new therapy for patients. This progression may influence investor interest in genetically-focused biopharma stocks.